December 2023 in “European Journal of Pharmacology” C3G and Vitisin A may help prevent hair loss by blocking male hormones and stopping hair cell death.
December 2022 in “Journal of Natural Remedies” Cucurbita maxima seed extract shows promise for breast cancer treatment.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
October 2024 in “Journal of the Endocrine Society” Certain genetic variants reduce enzyme activity, contributing to non-classic congenital adrenal hyperplasia.
33 citations
,
August 2000 in “Experimental Cell Research”
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
39 citations
,
August 2004 in “International journal of gynaecology and obstetrics” Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
July 2007 in “Journal of Generic Medicines” The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
January 2025 in “Turkish Journal of Cerebrovascular Diseases” CARASIL can cause different symptoms even with the same genetic mutation.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
108 citations
,
April 2004 in “Medicinal Research Reviews” Steroid sulfatase inhibitors could help treat hormone-related disorders and cancers.
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.
January 2022 in “Essentials in ophthalmology” Tamsulosin increases the risk of floppy iris syndrome during cataract surgery.
6 citations
,
August 2016 in “Journal of Visualized Experiments” The CUBIC protocol allows detailed 3D visualization of proteins in mouse skin biopsies.
January 2025 in “Transplantation” Stopping antifungal prophylaxis after 1 year may be safe for low-risk transplant patients.
24 citations
,
May 2006 in “Proceedings of the National Academy of Sciences of the United States of America” Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.
2 citations
,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
1 citations
,
September 2023 in “Applied sciences (Basel)” Ishige sinicola extract may help prevent muscle atrophy through its antioxidant and anti-inflammatory effects.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” New inhibitors may reduce gut toxicity from cancer drugs.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
4 citations
,
October 2020 in “Toxicology Mechanisms and Methods” Hesperidin protects rat testicles from finasteride damage and improves sperm health.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”